← Back to CMMB filing summaryOriginal filing text · Part I
Item 11 — Quantitative and Qualitative Disclosures About Market Risk
Chemomab Therapeutics Ltd. · 20-F · FY 2025 · Period ended Dec 31, 2025
View complete filing on SEC EDGAR ↗This is the extracted source text from the SEC filing. Formatting may differ from the original document.
Qualitative Disclosures about Market Risk
We are exposed to market risk from changes in exchange rates, interest
rates and inflation. All of these market risks arise in the ordinary course of business, as we do not engage in speculative trading activities.
The following analysis provides additional information regarding these risks.
Interest rate risk
Our investments are subject to market risk due to changes in interest
rates, which may affect our interest income and fair market value of our investments. To minimize this risk, we maintain our portfolio
in a variety of high-grade securities, including U.S. treasury bonds and government agencies. The primary objectives of our investment
activities are to support liquidity, preserve principal and to maximize income without significantly increasing risk.
As of December 31, 2025, we had $10.4 million of cash and cash
equivalent, bank deposits and marketable securities. Interest-earning instruments carry a degree of interest rate risk. However, our historical
interest income has not fluctuated significantly. A hypothetical 10% change in interest rates would not have had a material impact on
our financial results for the years ended December 31, 2024 and 2025. We do not enter into investments for trading or speculative purposes
and have not used any derivative financial instruments to manage our interest rate risk exposure.
Foreign Currency Exchange Risk
Our functional currency is the U.S. Dollar. We are exposed to foreign
exchange rate risk. We are located in Israel, where part of our general and administrative expenses costs is incurred in New Israeli Shekels.
During each of the years ended December 31, 2025, and 2024, we recognized foreign currency transaction gain of $125 thousand and $9 thousand,
respectively, respectively. These foreign currency transaction gains were recorded in financial expenses. We believe that a 10% change
in the exchange rate between the U.S. Dollar and New Israeli Shekel would not have a material impact on our financial position or results
of operations.
As we continue to grow our business, our results of operations
and cash flows will be subject to fluctuations due to changes in foreign currency exchange rates, which could adversely impact our results
of operations. To date, we have not entered into any foreign currency hedging contracts to mitigate our exposure to foreign currency exchange
risk.